{"id":13266,"date":"2024-08-23T02:26:47","date_gmt":"2024-08-23T00:26:47","guid":{"rendered":"https:\/\/valintermed.com\/?p=13266"},"modified":"2024-08-23T02:26:47","modified_gmt":"2024-08-23T00:26:47","slug":"tubulyarnaya-agregirovannaya-miopatiya","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/","title":{"rendered":"Tubular aggregate myopathy"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Tubular aggregated myopathy (TAM) is a rare hereditary disease that manifests itself in the disruption of the myofibrillar structure of skeletal muscles. This disease is characterized by a failure in the normal functioning of myocytes, which leads to their weakening and subsequent destruction. Clinically, TAM can manifest itself as muscle weakness, fatigue, spasticity and impaired motor activity. Tubular aggregated myopathy is associated with abnormalities in the structure of myofibrils, which allows diagnosing the disease based on morphological analysis of muscle tissue. Despite its rarity, TAM is a significant problem in the field of neuromuscular diseases, requiring an integrated approach to diagnosis and treatment.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/tubular-aggregation-myopathy\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tubular aggregated myopathy was first described in the late 20th century when studies of muscle tissue morphology identified specific changes associated with the disease. Early clinical observations indicated structural abnormalities in myofibrils, which became the basis for further research. Interestingly, new molecular techniques became available in the 1990s, which allowed the genetic basis of the disorder to be established and specific mutations to be identified.<\/p>\n<p>In recent decades, TAM has been the subject of scientific research, which has allowed not only a deeper understanding of the mechanism of its development, but also to establish links with other myopathies. It is noteworthy that among scientific publications devoted to TAM, there are works revealing the relationship of this disease with neuropathies and other muscle disorders, which confirms the diversity and complexity of the clinical picture.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tubular aggregated myopathy is a rare disease, and estimating its prevalence is difficult. There are limited population-based data available in the medical literature. The overall prevalence estimate is approximately 1 in 100,000 population, but actual figures may vary based on ethnicity and other factors.<\/p>\n<p>It is known that this type of myopathy is more often observed in representatives of certain family groups, which indicates the presence of a hereditary predisposition. Statistical data indicate that among patients with myopathies, tubular aggregated myopathy accounts for about 5-10% cases, but more accurate data require further research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tubular aggregate myopathy is associated with mutations in several genes that code for proteins responsible for maintaining the structure of muscle fibers. The most common are mutations in genes encoding myosin and actin proteins. The main genes involved include:<\/p>\n<ul>\n<li>MYH7 is a gene encoding beta-myosin;<\/li>\n<li>ACTA1 is a gene encoding alpha-actin;<\/li>\n<li>TPM3 is the gene encoding tropomyosin.<\/li>\n<\/ul>\n<p>These mutations lead to disruption of the normal structure of myofibrils and their aggregation, which is the pathogenetic basis of the disease. Genetic tests can help in diagnosing and prognosticating the course of the disease, as well as in assessing the risk of transmission of the disease among family members.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Risk factors for developing tubular aggregate myopathy are mainly related to hereditary aspects and genetic predisposition, however there are other potential triggers including:<\/p>\n<ul>\n<li>Family history of the disease;<\/li>\n<li>Presence of other myopathies in the family;<\/li>\n<li>Exposure of the body to toxic substances and chemicals;<\/li>\n<li>Extreme physical activity, which can aggravate the course of the disease;<\/li>\n<li>Viral infections that can activate genetic predispositions.<\/li>\n<\/ul>\n<p>Thus, a high predisposition to the disease within certain family groups and the influence of environmental factors may contribute to the development of TAM.<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of tubular aggregated myopathy is based on a combination of clinical and laboratory testing, including:<\/p>\n<ul>\n<li>The main symptoms may include muscle weakness, increased fatigue, spastic manifestations;<\/li>\n<li>Laboratory tests, including blood chemistry tests for creatine kinase levels and other markers of muscular dystrophy;<\/li>\n<li>Radiological tests such as magnetic resonance imaging, which can visualize changes in muscles;<\/li>\n<li>Muscle tissue biopsy, which is a key diagnostic method, revealing characteristic dystrophic changes;<\/li>\n<li>Differential diagnosis with other myopathies and neuropathies, which helps to exclude alternative causes of symptoms.<\/li>\n<\/ul>\n<p>A complete clinical and laboratory examination allows for a correct diagnosis and appropriate treatment methods to be determined.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of tubular aggregated myopathy depends on the severity of the disease and is prescribed individually for each patient. The main approaches to treatment include:<\/p>\n<ul>\n<li>General treatment includes rehabilitation measures aimed at maintaining muscle activity and functionality;<\/li>\n<li>Pharmacological treatment is aimed at relieving symptoms and may include muscle relaxants and anti-inflammatory drugs;<\/li>\n<li>Surgical treatment may be considered if severe disorders are detected that require surgical correction;<\/li>\n<li>Other treatments, such as physical therapy and various exercise training methods, help improve patients&#039; quality of life.<\/li>\n<\/ul>\n<p>Regular monitoring of the patient&#039;s condition is necessary to assess the effectiveness of therapy and the need for adjustments to the treatment plan.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The main drugs used in the treatment of tubular aggregated myopathy include:<\/p>\n<ul>\n<li>Corticosteroids - to reduce inflammation;<\/li>\n<li>Muscle relaxants - to relieve spastic symptoms;<\/li>\n<li>Neuroprotectors that help improve metabolism and restore muscle cells;<\/li>\n<li>Anti-inflammatory drugs - to eliminate pain and inflammatory changes.<\/li>\n<\/ul>\n<p>These drugs are prescribed taking into account the individual characteristics of the patient and should be used under the supervision of a physician.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring of patients with tubular aggregated myopathy includes regular follow-up examinations and assessment of disease progression:<\/p>\n<ul>\n<li>Control stages are carried out using clinical and laboratory methods to assess muscle condition and function;<\/li>\n<li>The prognosis may vary depending on the severity of the disease and the effectiveness of treatment;<\/li>\n<li>Complications may include progressive muscle weakness, leading to decreased quality of life and limited physical activity.<\/li>\n<\/ul>\n<p>An integrated approach to patient monitoring and management helps improve outcomes and enhance quality of life.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tubular aggregated myopathy can manifest itself in both childhood and adulthood, but the course of the disease may differ:<\/p>\n<ul>\n<li>In children, the disease often manifests itself at the beginning of the development of motor skills, which can cause concern for parents;<\/li>\n<li>In adult patients, symptoms may develop slowly and are often perceived as normal part of aging;<\/li>\n<li>In older patients, progressive muscle weakness can significantly complicate daily life and affect overall body function.<\/li>\n<\/ul>\n<p>The specificity of manifestations and available treatment methods require an individual approach to each age group.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What is tubular aggregate myopathy?<\/strong><br \/>\n        Tubular aggregated myopathy is a rare inherited disease characterized by a disruption of the structure of myofibrils and manifested by muscle weakness and fatigue.<\/li>\n<li><strong>What are the main symptoms of the disease?<\/strong><br \/>\n        The main symptoms are muscle weakness, increased fatigue, spastic manifestations and limited mobility.<\/li>\n<li><strong>How is tubular aggregated myopathy diagnosed?<\/strong><br \/>\n        Diagnosis includes clinical examination, laboratory tests for creatine kinase levels, muscle biopsy, and radiological examinations.<\/li>\n<li><strong>What treatments are available to treat this disease?<\/strong><br \/>\n        Treatment includes rehabilitation measures, pharmacological therapy, physical therapy and, in some cases, surgery.<\/li>\n<li><strong>What is the prognosis for patients with tubular aggregate myopathy?<\/strong><br \/>\n        The prognosis varies depending on the severity of the disease and the effectiveness of treatment, but with timely diagnosis and treatment, improvements in quality of life are possible.<\/li>\n<\/ul>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Tubular aggregate myopathy (TAM) is a rare inherited disorder that involves the disruption of the myofibrillar structure of skeletal muscle. The disorder is characterized by a failure<\/p>","protected":false},"author":1,"featured_media":23875,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-13266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/13266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=13266"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/13266\/revisions"}],"predecessor-version":[{"id":13654,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/13266\/revisions\/13654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/23875"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=13266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=13266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=13266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}